Sinotau (先通医药) Pre-IPO: A Niche Radiopharmaceutical Player
China's Sinotau aims to raise $100 million through a Hong Kong listing with CICC as book runner. We explores its core products, pre-IPO investors,...
437 Views
China Healthcare Weekly (May.5) - Overvaluation in Primary Market, RDC to Be Hot Spot, Yiling Pharma
Only foreign markets are able to “digest” high valuation of China's biotech assets in primary market. RDC/RLT will become the next hot area for...
571 Views
Hepalink Pharma IPO: Trading Debut
Shenzhen HepaLink Pharmaceuticals (H) (HEPALINK HK) is a leading China-based pharmaceutical company with global businesses in pharmaceutical,...
485 Views
Hepalink Pharma IPO: Valuation Insights
Shenzhen HepaLink Pharmaceuticals (H) (HEPALINK HK) is a leading China-based pharmaceutical company with global businesses in pharmaceutical,...
587 Views
Falling Fertility Adds to China's Population Woes
By allowing couples to have up to two children China hopes to reverse its likely population decline. But falling fertility and the pressures of...
4.2k Views